SPOTLIGHT -
May 9th 2024
Cencora’s vice president of product management, global products & solutions Beth Riggio discusses the issues the industry faces with recalls and how it can improve.
May 2nd 2024
The CEO of Outcomes discusses how local pharmacies are playing an important role in improving health equity.
April 19th 2024
Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
April 18th 2024
Unique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.
March 4th 2024
Stark discusses how the ways that data is reshaping commercial strategies.
The Amazon Effect: A Data-Fueled Customer Experience
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value
Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Bridging the Generational Chasm in Oncology
How engaging with digital influencers holds the key for medical affairs.
Bringing Biosimilars to Market in Europe
If the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.
How Just-in-Time Data Can Clear the Path to First Drug Launch
Implementing an efficient means of unifying disparate data and allowing teams to utilize this single source of truth data will allow them to track KPIs more effectively and get key insights when they need them.
Critical Connection: Patient Services and Product Launch
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Mastering the Transition From Academia to Industry
Tips for rounding out the rough edges in crossover.
Injecting Traditional Scientific Exchange with New Life
Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.
Commercial Sustainability of Pharmaceutical Innovations for Pandemics
Assessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Best Practices for Balancing Medical Affairs Globalization with Local Requirements
Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Manage Risk Effectively to Improve the Value of Your Alliance
In this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Planning Ahead for a Post COVID-19 Workforce and Workplace
Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.
Drug Launch: Winning the Evidence Battle
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
New Standards for First-to-Launch Players
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
(O)mega Opportunity: Vascepa
Uncovering fish oil derivative’s benefit for heart health.
Educational Mission: Oxbryta
New hope accompanies overdue recognition in sickle cell disease fight.
One Time for Lifetime: Zolgensma
The world’s most expensive drug put in context.
Unlocked Potential — ‘Keying’ in On New-Era Engagement
How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
Staying the Course in Product Launch
Amid pandemic, rely on the fundamentals.
Commercializing an Orphan Drug: Why “Just” Serving a High Unmet Medical Need Won’t Do the Job
Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 Pandemic
A look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
How Pharma Reps and Managers Can Work to Overcome the In-Person HCP Barrier
While HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.
The Impact of Accelerated Drug Development
Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.
Tapping Compliance Data to Drive Success
How pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.
Strategic Realignment for a Better Future
In adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.
Launching during Lockdown
Immunomedics’ CFO/CBO Usama Malik discusses how a lot of good planning and a little good fortune helped the company to achieve its “virtual launch” amid the coronavirus crisis.
Culture and Compliance: Building a Culture of Business Ethics
Amid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.
Pharma CEO Leadership During the Pandemic
A recent roundtable of pharmaceutical CEOs, and moderated by Dr. Scott Gottlieb, discussed pressing concerns around the pandemic, including clinical trials, product launches, keeping employees safe and the future of the pharmaceutical industry.
Research Reveals New Launch Standards for First-to-Launch Pharma and Biotech Companies in the U.S.
While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.
Outlining Current and Future Trends in Medical Information
With the role of Medical Information in pharma companies changing in recent years, this article outlines some current and future trends including globalization and the use of data to drive change.